Kidney TransplantFOLLOW-KTxNCT07842289
AI-Assisted vs Usual Follow-up in Kidney Transplantation
A study testing AI-Assisted Follow-up Consultation and Usual Physician-Led Follow-up Consultation in people with Kidney Transplant and Transplant Recipients, run by UPECLIN HC FM Botucatu Unesp at 1 site in Brazil.
Trial summary
The goal of this clinical trial is to learn whether kidney transplant follow-up visits run by a health professional using an artificial intelligence (AI) computer helper are as good as usual follow-up visits with a doctor. People who receive a kidney transplant need check-up visits for the rest of their lives. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Kidney Transplant, Transplant Recipients
- What is being tested?
- AI-Assisted Follow-up Consultation and Usual Physician-Led Follow-up Consultation
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 140 participants
- Where
- 1 siteBrazil
- Study dates
- 1 Feb 2027to 1 Jun 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults aged 18 years or older
- Have a working kidney transplant
- Received the kidney transplant at least 6 months ago
- Able to take part in a routine follow-up visit on their own
- Able to understand the study and give informed consent
Who cannot join
- Have a sudden or serious illness that needs urgent care
- Have a thinking or sensory problem that means they need another person's help during the visit
- Cannot communicate in Portuguese, the language used in the study
- Are taking part in another study that would conflict with this one
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Brazil1 site
UPECLIN
Botucatu, São Paulo, 18618-686
Ana Paola Piloto Oliveira, doctorade, +55(14) 3880 -1686, paola.piloto@unesp.br
About this study
The goal of this clinical trial is to learn whether kidney transplant follow-up visits run by a health professional using an artificial intelligence (AI) computer helper are as good as usual follow-up visits with a doctor.
People who receive a kidney transplant need check-up visits for the rest of their lives. These visits help keep the new kidney working well. As more people live longer with a transplant, clinics get busier. An AI helper may make visits more consistent and free up doctor time. This idea has not yet been tested well in real clinics.
Read more
The main questions this study will answer are:
Are AI-assisted visits as good as usual doctor visits? Trained reviewers will rate the quality of each visit. The reviewers will not know which type of visit they are rating.
Are patients as satisfied with their visit? How long does the visit take, and how much time does the clinician spend on paperwork? Do the visits do a better job of checking key items, such as screening tests, vaccines, and transplant medicines? Are the visits safe for patients?
Adults can take part if they have a working kidney transplant, if the transplant was at least 6 months ago, and if they can complete a routine visit on their own.
Researchers will place 140 adults into two groups by chance, like flipping a coin. One group will have a visit run by a health professional who uses the AI helper. The other group will have a usual visit with a doctor. In both groups, the AI cannot order tests, change medicines, or make a diagnosis on its own. A clinician checks and approves everything.
Participants will take part in one study follow-up visit. The visit will be audio-recorded so reviewers can rate it later. After the visit, participants will fill out a short satisfaction survey on a tablet.
Read the detailed description
Rationale. Kidney transplant recipients require lifelong, protocol-driven outpatient follow-up. After the first 6 to 12 months, care of stable recipients becomes standardized, and a large share of each routine visit is spent on standardizable tasks: laboratory review, immunosuppression reconciliation, screening and vaccination checks, and clinical documentation. Growing recipient numbers, a shortage of nephrologists, and the concentration of specialists in tertiary centers lengthen follow-up intervals, particularly within the Brazilian Unified Health System (SUS). Large language models (LLMs) have shown promise on patient-facing tasks, but existing evidence derives mainly from vignette- or forum-based comparisons, without real-workflow evaluation, prospective safety endpoints, or blinded quality instruments. A retrieval-augmented generation (RAG) architecture that grounds model outputs in an indexed base of guidelines and institutional protocols, with verifiable citations and explicit uncertainty flagging, addresses hallucination risk and enables auditable, specialty-specific use. This trial moves the evaluation of LLM support from vignettes to a real ambulatory workflow under mandatory human supervision.
Study design and setting. This is a randomized, controlled, parallel-group, non-inferiority trial conducted at the kidney transplant outpatient clinic of the Faculdade de Medicina de Botucatu, Universidade Estadual Paulista (UNESP), Brazil. Reporting follows the CONSORT 2010 statement. Allocation is 1:1 to an AI-assisted follow-up consultation or a usual physician-led consultation.
Intervention (AI-assisted arm). A trained health professional conducts the routine follow-up consultation while a specialized LLM assistant provides real-time support. The assistant is built on a general-purpose LLM adapted for clinical dialogue and operates through a RAG pipeline that indexes KDIGO guidelines and clinic standard operating procedures. During the encounter the assistant supplies a structured content checklist, guideline-anchored suggestions with source citations, uncertainty flags, and a draft structured clinical note and orders. Guardrails prevent the assistant from finalizing medication changes, orders, or diagnoses. Every proposed action is flagged for clinician review; the responsible clinician verifies vital signs and findings, corrects inaccuracies, and co-signs the encounter before any action is enacted (human-in-the-loop). Transcripts and structured data are stored in the electronic data capture system.
Comparator (usual-care arm). Standard physician-led transplant follow-up per routine clinic practice and current guidelines, comprising history, medication reconciliation with a focus on immunosuppression, focused examination, and management plan.
To limit performance bias, both arms follow an identical pre-specified content checklist and target a similar consultation duration. All consultations are audio-recorded to permit later blinded assessment.
Randomization, allocation concealment, and masking. A computer-generated randomization sequence with variable block sizes is implemented in REDCap; sequentially numbered, opaque, sealed envelopes serve as an offline contingency. Allocation remains concealed until assignment. Because the nature of the intervention precludes masking of participants and treating clinicians, masking is applied to the outcome assessors and to the statistician. Trained raters who score consultation quality are blinded to allocation, as is the analyst.
Sample size. The trial is powered on the primary outcome, the MAAS-Global total score (range 0 to 6). Using a pre-specified non-inferiority margin of 0.5 points, an assumed common standard deviation of 1.0, one-sided alpha of 0.025, 80% power, and 1:1 allocation, 63 participants per arm are required. Allowing for 10% loss or withdrawal yields 70 participants per arm, for a planned total of 140.
Statistical analysis. Analyses follow the intention-to-treat principle. Continuous outcomes are analyzed with linear regression or mixed-effects models, with a fixed effect for group, pre-specified optional covariates (age, sex, and time since transplant), and, where applicable, a random intercept for rater. Non-inferiority for the primary outcome is assessed from the two-sided 95% confidence interval for the adjusted mean difference (AI-assisted minus usual care); non-inferiority is concluded if the lower confidence bound exceeds the margin of -0.5. Binary outcomes are compared using risk differences with 95% confidence intervals. Missing data are addressed with multiple imputation when missingness exceeds 5% and is plausibly missing at random. Two-sided p-values are reported, with emphasis on effect sizes and confidence intervals. A detailed statistical analysis plan is finalized before database lock.
Data management and quality assurance. Study data are collected and managed in REDCap. To estimate inter-rater reliability, two independent raters score 20% of consultations in duplicate; disagreement greater than 1 point on any item triggers adjudication and rater retraining. The patient satisfaction questionnaire is self-administered on a tablet immediately after the consultation, without staff assistance, to preserve independence. Consultation timing data are captured for each encounter to support the efficiency analyses. Data handling complies with the Brazilian General Data Protection Law (LGPD), and safety is monitored continuously throughout enrollment.
Duration. The project is planned for 36 months, spanning system development and RAG indexing, cross-cultural adaptation of the satisfaction instrument, rater training and calibration, a stabilization pilot, enrollment and data collection, analysis, and dissemination.
- Conditions
- Kidney Transplant, Transplant Recipients
- Being tested
- AI-Assisted Follow-up Consultation, Usual Physician-Led Follow-up Consultation
- Keywords
- Large Language Model, Clinical Decision Support, Kidney Transplant Follow-up, Non-Inferiority Trial, Patient Satisfaction
- Medical subject headings
- Patient Satisfaction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AI-Assisted Follow-up ConsultationOther
A specialized large language model (LLM) assistant supports the consulting health professional in real time during a routine kidney transplant follow-up consultation. The assistant uses a retrieval-augmented generation (RAG) pipeline indexed on KDIGO guidelines and clinic standard operating procedures, and provides a structured content checklist, guideline-anchored suggestions with source citations, uncertainty flags, and a draft structured clinical note and orders. Guardrails prevent the assistant from finalizing medication changes, orders, or diagnoses. The responsible clinician reviews and verifies all findings, corrects inaccuracies, and approves and co-signs the encounter before any action is enacted (human-in-the-loop).
Usual Physician-Led Follow-up ConsultationOther
Standard physician-led kidney transplant follow-up according to routine clinic practice and current guidelines, without the AI assistant. The consultation comprises history-taking, medication reconciliation with a focus on immunosuppression, focused examination, and a management plan, following the same pre-specified content checklist as the experimental arm.
| Study group | Role | What they receive |
|---|---|---|
| AI-Assisted Follow-up Consultation | Experimental | In this arm, a trained health professional conducts the routine follow-up consultation while a specialized large language model (LLM) assistant provides real-time support. The assistant uses a retrieval-augmented generation (RAG) pipeline indexed on KDIGO guidelines and clinic standard operating procedures, and supplies a structured content checklist, guideline-anchored suggestions with source citations, uncertainty flags, and a draft structured clinical note and orders. Guardrails prevent the assistant from finalizing medication changes, orders, or diagnoses. The responsible clinician reviews and verifies all findings, corrects inaccuracies, and approves and co-signs the encounter before any action is enacted (human-in-the-loop). The consultation follows a pre-specified content checklist and is audio-recorded for later blinded quality assessment. Receives: Other: AI-Assisted Follow-up Consultation |
| Usual Physician-Led Follow-up | Active comparator | In this arm, participants receive standard physician-led kidney transplant follow-up according to routine clinic practice and current guidelines, without the AI assistant. The consultation comprises history-taking, medication reconciliation with a focus on immunosuppression, focused examination, and a management plan. The consultation follows the same pre-specified content checklist and targets a similar duration to the AI-assisted arm, and is audio-recorded for later blinded quality assessment. Receives: Other: Usual Physician-Led Follow-up Consultation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Consultation quality measured by the MAAS-Global global score
Overall quality of the follow-up consultation, scored with the MAAS-Global instrument, a validated tool for rating clinician consultation skills. Consultation quality is reported as the MAAS-Global global score, which ranges from 0 to 6, where 0 indicates the poorest consultation quality and 6 indicates the highest consultation quality (higher scores indicate better quality). Consultations are audio-recorded and scored by trained raters who are blinded to group allocation. This is the primary endpoint for the non-inferiority comparison between the AI-assisted consultation and the usual physician-led consultation.
Measured: Consultation quality measured at Day 1
Secondary outcomes (1)
Patient satisfaction measured by the VSQ-9
Participant satisfaction with the consultation, measured with the Visit-Specific Satisfaction Questionnaire (VSQ-9), self-administered on a tablet immediately after the visit without staff assistance. Each item is scored on a 5-point scale and transformed to a 0 to 100 metric; the total score is the mean of the answered items and ranges from 0 to 100, where 0 indicates the lowest satisfaction and 100 indicates the highest satisfaction (higher scores indicate greater satisfaction).
Measured: Patient satisfaction at day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Sep 2026
- Study start1 Feb 2027 (estimated)
- Primary completion1 Apr 2028 (estimated)
- Study completion1 Jun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Kidney TransplantStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Two-arm, parallel-group, randomized, controlled non-inferiority trial with 1:1 allocation. Participants are assigned to either a health professional-led follow-up consultation supported in real time by a large language model with retrieval-augmented generation (AI-assisted arm) or a usual physician-led follow-up consultation (usual-care arm). Each participant takes part in a single study follow-up consultation. Because the nature of the intervention prevents masking of participants and treating clinicians, blinding is applied to the outcome assessors who rate consultation quality and to the statistician. Both arms follow an identical pre-specified content checklist and target a similar consultation duration to limit performance bias.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 140 participants (estimated)
Sponsor and investigators
- Lead sponsor
- UPECLIN HC FM Botucatu Unesp
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07842289
- Sponsor's protocol ID
- 93899225.2.0000.5411
- Acronym
- FOLLOW-KTx
- Status last verified
- Sep 2026
- First submitted
- 16 Sep 2026
- Last updated
- 25 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: A decision has not yet been made. The study collects audio recordings of consultations and other sensitive data from kidney transplant recipients, and any individual-level sharing must first be reconciled with participant confidentiality, the scope of the informed consent, ethics committee approval, and the Brazilian General Data Protection Law (LGPD). The sharing plan will be finalized in the study Data Management Plan before database lock.
Publications
Rubin HR, Gandek B, Rogers WH, Kosinski M, McHorney CA, Ware JE Jr. Patients' ratings of outpatient visits in different practice settings. Results from the Medical Outcomes Study. JAMA. 1993 Aug 18;270(7):835-40.
PubMed 8340982van Es JM, Schrijver CJ, Oberink RH, Visser MR. Two-dimensional structure of the MAAS-Global rating list for consultation skills of doctors. Med Teach. 2012;34(12):e794-9. doi: 10.3109/0142159X.2012.709652. Epub 2012 Sep 3.
PubMed 22938687Miao J, Thongprayoon C, Suppadungsuk S, Garcia Valencia OA, Cheungpasitporn W. Integrating Retrieval-Augmented Generation with Large Language Models in Nephrology: Advancing Practical Applications. Medicina (Kaunas). 2024 Mar 8;60(3):445. doi: 10.3390/medicina60030445.
PubMed 38541171Ayers JW, Poliak A, Dredze M, Leas EC, Zhu Z, Kelley JB, Faix DJ, Goodman AM, Longhurst CA, Hogarth M, Smith DM. Comparing Physician and Artificial Intelligence Chatbot Responses to Patient Questions Posted to a Public Social Media Forum. JAMA Intern Med. 2023 Jun 1;183(6):589-596. doi: 10.1001/jamainternmed.2023.1838.
PubMed 37115527Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009 Nov;9 Suppl 3:S1-155. doi: 10.1111/j.1600-6143.2009.02834.x.
PubMed 19845597
Study at a glance
From the registry record, last updated by the sponsor on 25 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- AI-Assisted vs Usual Follow-up in Kidney Transplantation
- ClinicalTrials.gov ID
- NCT07842289
- Acronym / sponsor ID
- FOLLOW-KTx / 93899225.2.0000.5411
- Conditions
- Kidney Transplant, Transplant Recipients
- Keywords
- Large Language Model, Clinical Decision Support, Kidney Transplant Follow-up, Non-Inferiority Trial, Patient Satisfaction
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 140 participants (estimated)
- Lead sponsor
- UPECLIN HC FM Botucatu UnespUniversity, hospital or other
- Study start
- 1 Feb 2027 (estimated)
- Primary completion
- 1 Apr 2028 (estimated)
- Study completion
- 1 Jun 2028 (estimated)
- First posted
- 25 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn whether kidney transplant follow-up visits run by a health professional using an artificial intelligence (AI) computer helper are as good as usual follow-up visits with a doctor.
People who receive a kidney transplant need check-up visits for the rest of their lives. These visits help keep the new kidney working well. As more people live longer with a transplant, clinics get busier. An AI helper may make visits more consistent and free up doctor time. This idea has not yet been tested well in real clinics.
The main questions this study will answer are:
Are AI-assisted visits as good as usual doctor visits? Trained reviewers will rate the quality of each visit. The reviewers will not know which type of visit they are rating.
Are patients as satisfied with their visit? How long does the visit take, and how much time does the clinician spend on paperwork? Do the visits do a better job of checking key items, such as screening tests, vaccines, and transplant medicines? Are the visits safe for patients?
Adults can take part if they have a working kidney transplant, if the transplant was at least 6 months ago, and if they can complete a routine visit on their own.
Researchers will place 140 adults into two groups by chance, like flipping a coin. One group will have a visit run by a health professional who uses the AI helper. The other group will have a usual visit with a doctor. In both groups, the AI cannot order tests, change medicines, or make a diagnosis on its own. A clinician checks and approves everything.
Participants will take part in one study follow-up visit. The visit will be audio-recorded so reviewers can rate it later. After the visit, participants will fill out a short satisfaction survey on a tablet.
Detailed description
Rationale. Kidney transplant recipients require lifelong, protocol-driven outpatient follow-up. After the first 6 to 12 months, care of stable recipients becomes standardized, and a large share of each routine visit is spent on standardizable tasks: laboratory review, immunosuppression reconciliation, screening and vaccination checks, and clinical documentation. Growing recipient numbers, a shortage of nephrologists, and the concentration of specialists in tertiary centers lengthen follow-up intervals, particularly within the Brazilian Unified Health System (SUS). Large language models (LLMs) have shown promise on patient-facing tasks, but existing evidence derives mainly from vignette- or forum-based comparisons, without real-workflow evaluation, prospective safety endpoints, or blinded quality instruments. A retrieval-augmented generation (RAG) architecture that grounds model outputs in an indexed base of guidelines and institutional protocols, with verifiable citations and explicit uncertainty flagging, addresses hallucination risk and enables auditable, specialty-specific use. This trial moves the evaluation of LLM support from vignettes to a real ambulatory workflow under mandatory human supervision.
Study design and setting. This is a randomized, controlled, parallel-group, non-inferiority trial conducted at the kidney transplant outpatient clinic of the Faculdade de Medicina de Botucatu, Universidade Estadual Paulista (UNESP), Brazil. Reporting follows the CONSORT 2010 statement. Allocation is 1:1 to an AI-assisted follow-up consultation or a usual physician-led consultation.
Intervention (AI-assisted arm). A trained health professional conducts the routine follow-up consultation while a specialized LLM assistant provides real-time support. The assistant is built on a general-purpose LLM adapted for clinical dialogue and operates through a RAG pipeline that indexes KDIGO guidelines and clinic standard operating procedures. During the encounter the assistant supplies a structured content checklist, guideline-anchored suggestions with source citations, uncertainty flags, and a draft structured clinical note and orders. Guardrails prevent the assistant from finalizing medication changes, orders, or diagnoses. Every proposed action is flagged for clinician review; the responsible clinician verifies vital signs and findings, corrects inaccuracies, and co-signs the encounter before any action is enacted (human-in-the-loop). Transcripts and structured data are stored in the electronic data capture system.
Comparator (usual-care arm). Standard physician-led transplant follow-up per routine clinic practice and current guidelines, comprising history, medication reconciliation with a focus on immunosuppression, focused examination, and management plan.
To limit performance bias, both arms follow an identical pre-specified content checklist and target a similar consultation duration. All consultations are audio-recorded to permit later blinded assessment.
Randomization, allocation concealment, and masking. A computer-generated randomization sequence with variable block sizes is implemented in REDCap; sequentially numbered, opaque, sealed envelopes serve as an offline contingency. Allocation remains concealed until assignment. Because the nature of the intervention precludes masking of participants and treating clinicians, masking is applied to the outcome assessors and to the statistician. Trained raters who score consultation quality are blinded to allocation, as is the analyst.
Sample size. The trial is powered on the primary outcome, the MAAS-Global total score (range 0 to 6). Using a pre-specified non-inferiority margin of 0.5 points, an assumed common standard deviation of 1.0, one-sided alpha of 0.025, 80% power, and 1:1 allocation, 63 participants per arm are required. Allowing for 10% loss or withdrawal yields 70 participants per arm, for a planned total of 140.
Statistical analysis. Analyses follow the intention-to-treat principle. Continuous outcomes are analyzed with linear regression or mixed-effects models, with a fixed effect for group, pre-specified optional covariates (age, sex, and time since transplant), and, where applicable, a random intercept for rater. Non-inferiority for the primary outcome is assessed from the two-sided 95% confidence interval for the adjusted mean difference (AI-assisted minus usual care); non-inferiority is concluded if the lower confidence bound exceeds the margin of -0.5. Binary outcomes are compared using risk differences with 95% confidence intervals. Missing data are addressed with multiple imputation when missingness exceeds 5% and is plausibly missing at random. Two-sided p-values are reported, with emphasis on effect sizes and confidence intervals. A detailed statistical analysis plan is finalized before database lock.
Data management and quality assurance. Study data are collected and managed in REDCap. To estimate inter-rater reliability, two independent raters score 20% of consultations in duplicate; disagreement greater than 1 point on any item triggers adjudication and rater retraining. The patient satisfaction questionnaire is self-administered on a tablet immediately after the consultation, without staff assistance, to preserve independence. Consultation timing data are captured for each encounter to support the efficiency analyses. Data handling complies with the Brazilian General Data Protection Law (LGPD), and safety is monitored continuously throughout enrollment.
Duration. The project is planned for 36 months, spanning system development and RAG indexing, cross-cultural adaptation of the satisfaction instrument, rater training and calibration, a stabilization pilot, enrollment and data collection, analysis, and dissemination.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- Two-arm, parallel-group, randomized, controlled non-inferiority trial with 1:1 allocation. Participants are assigned to either a health professional-led follow-up consultation supported in real time by a large language model with retrieval-augmented generation (AI-assisted arm) or a usual physician-led follow-up consultation (usual-care arm). Each participant takes part in a single study follow-up consultation. Because the nature of the intervention prevents masking of participants and treating clinicians, blinding is applied to the outcome assessors who rate consultation quality and to the statistician. Both arms follow an identical pre-specified content checklist and target a similar consultation duration to limit performance bias.
| Arm | Type | Receives |
|---|---|---|
| AI-Assisted Follow-up Consultation | Experimental | Other: AI-Assisted Follow-up ConsultationIn this arm, a trained health professional conducts the routine follow-up consultation while a specialized large language model (LLM) assistant provides real-time support. The assistant uses a retrieval-augmented generation (RAG) pipeline indexed on KDIGO guidelines and clinic standard operating procedures, and supplies a structured content checklist, guideline-anchored suggestions with source citations, uncertainty flags, and a draft structured clinical note and orders. Guardrails prevent the assistant from finalizing medication changes, orders, or diagnoses. The responsible clinician reviews and verifies all findings, corrects inaccuracies, and approves and co-signs the encounter before any action is enacted (human-in-the-loop). The consultation follows a pre-specified content checklist and is audio-recorded for later blinded quality assessment. |
| Usual Physician-Led Follow-up | Active comparator | Other: Usual Physician-Led Follow-up ConsultationIn this arm, participants receive standard physician-led kidney transplant follow-up according to routine clinic practice and current guidelines, without the AI assistant. The consultation comprises history-taking, medication reconciliation with a focus on immunosuppression, focused examination, and a management plan. The consultation follows the same pre-specified content checklist and targets a similar duration to the AI-assisted arm, and is audio-recorded for later blinded quality assessment. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Adults aged 18 years or older
- Have a working kidney transplant
- Received the kidney transplant at least 6 months ago
- Able to take part in a routine follow-up visit on their own
- Able to understand the study and give informed consent
Key exclusion criteria (4 listed)
- Have a sudden or serious illness that needs urgent care
- Have a thinking or sensory problem that means they need another person's help during the visit
- Cannot communicate in Portuguese, the language used in the study
- Are taking part in another study that would conflict with this one
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AI-Assisted Follow-up ConsultationA specialized large language model (LLM) assistant supports the consulting health professional in real time during a routine kidney transplant follow-up consultation. The assistant uses a retrieval-augmented generation (RAG) pipeline indexed on KDIGO guidelines and clinic standard operating procedures, and provides a structured content checklist, guideline-anchored suggestions with source citations, uncertainty flags, and a draft structured clinical note and orders. Guardrails prevent the assistant from finalizing medication changes, orders, or diagnoses. The responsible clinician reviews and verifies all findings, corrects inaccuracies, and approves and co-signs the encounter before any action is enacted (human-in-the-loop). | Other | AI-Assisted Follow-up Consultation |
| Usual Physician-Led Follow-up ConsultationStandard physician-led kidney transplant follow-up according to routine clinic practice and current guidelines, without the AI assistant. The consultation comprises history-taking, medication reconciliation with a focus on immunosuppression, focused examination, and a management plan, following the same pre-specified content checklist as the experimental arm. | Other | Usual Physician-Led Follow-up |
Primary outcome
Consultation quality measured by the MAAS-Global global score
Time frame: Consultation quality measured at Day 1
Overall quality of the follow-up consultation, scored with the MAAS-Global instrument, a validated tool for rating clinician consultation skills. Consultation quality is reported as the MAAS-Global global score, which ranges from 0 to 6, where 0 indicates the poorest consultation quality and 6 indicates the highest consultation quality (higher scores indicate better quality). Consultations are audio-recorded and scored by trained raters who are blinded to group allocation. This is the primary endpoint for the non-inferiority comparison between the AI-assisted consultation and the usual physician-led consultation.
1 secondary outcome
Patient satisfaction measured by the VSQ-9
Time frame: Patient satisfaction at day 1
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Sep 2026.
- Background: PubMed 8340982Rubin HR, Gandek B, Rogers WH, Kosinski M, McHorney CA, Ware JE Jr. Patients' ratings of outpatient visits in different practice settings. Results from the Medical Outcomes Study. JAMA. 1993 Aug 18;270(7):835-40.
- Background: PubMed 22938687van Es JM, Schrijver CJ, Oberink RH, Visser MR. Two-dimensional structure of the MAAS-Global rating list for consultation skills of doctors. Med Teach. 2012;34(12):e794-9. doi: 10.3109/0142159X.2012.709652. Epub 2012 Sep 3.
- Background: PubMed 38541171Miao J, Thongprayoon C, Suppadungsuk S, Garcia Valencia OA, Cheungpasitporn W. Integrating Retrieval-Augmented Generation with Large Language Models in Nephrology: Advancing Practical Applications. Medicina (Kaunas). 2024 Mar 8;60(3):445. doi: 10.3390/medicina60030445.
- Background: PubMed 37115527Ayers JW, Poliak A, Dredze M, Leas EC, Zhu Z, Kelley JB, Faix DJ, Goodman AM, Longhurst CA, Hogarth M, Smith DM. Comparing Physician and Artificial Intelligence Chatbot Responses to Patient Questions Posted to a Public Social Media Forum. JAMA Intern Med. 2023 Jun 1;183(6):589-596. doi: 10.1001/jamainternmed.2023.1838.
- Background: PubMed 19845597Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009 Nov;9 Suppl 3:S1-155. doi: 10.1111/j.1600-6143.2009.02834.x.
- Individual participant dataSharing planned: No. A decision has not yet been made. The study collects audio recordings of consultations and other sensitive data from kidney transplant recipients, and any individual-level sharing must first be reconciled with participant confidentiality, the scope of the informed consent, ethics committee approval, and the Brazilian General Data Protection Law (LGPD). The sharing plan will be finalized in the study Data Management Plan before database lock.
Related trials for Kidney Transplant
Enrolling by invitation
Online Exercise Program for Transplant Patients: A Pilot Study
Kidney Transplantation, Physical Function
RecruitingPhase 2
A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant
Antibody-Mediated Rejection (AMR)
Not yet recruiting
Hypothermic Kidney Machine Perfusion With Omnisol
End Stage Renal Disease (ESRD), Kidney Transplant
Not yet recruitingEarly Phase 1
Biomarker-Guided Mycophenolate Mofetil Elimination in Low-Risk Older Adult Kidney Transplant Recipients
Kidney Transplant Recipient
Recruiting
Non-Invasive Monitoring of Pediatric Kidney Transplant Recipients and Immunosuppression Personalization: an Open-labeled Multicenter Randomized Controlled Study
Pediatric Kidney Disease, Transplant;Failure,Kidney
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing AI-Assisted Follow-up Consultation and Usual Physician-Led Follow-up Consultation in people with Kidney Transplant and Transplant Recipients, run by UPECLIN HC FM Botucatu Unesp at 1 site in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 25 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Luis Gustavo Modelli de Andrade, phD (+5514997980900, gustavo.modelli@unesp.br), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Consultation quality measured by the MAAS-Global global score (time frame: Consultation quality measured at Day 1). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07842289, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Sep 2026.